NASDAQ:AVGRAvinger Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avinger Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.52 -0.01 (-1.75 %) (As of 08/12/2020 11:36 AM ET) Add Compare Share Today's Range$0.50Now: $0.52▼$0.5450-Day Range$0.29MA: $0.39▼$0.5752-Week Range$0.24Now: $0.52▼$1.84Volume65,951 shsAverage Volume12.05 million shsMarket Capitalization$28.39 millionP/E RatioN/ADividend YieldN/ABeta1.47 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat, and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company sells and markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAvinger has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.40, Avinger has a potential upside of 168.1% from its current price of $0.52.Amount of Analyst CoverageAvinger has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAvinger has received 366 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAvinger has received 323 “underperform” votes. (Add your “underperform” vote.)Community SentimentAvinger has received 53.12% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Avinger and other stocks. Vote “Outperform” if you believe AVGR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVGR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAvinger does not currently pay a dividend.Dividend GrowthAvinger does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avinger insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.51% of the stock of Avinger is held by insiders.Percentage Held by InstitutionsOnly 7.21% of the stock of Avinger is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avinger are expected to grow in the coming year, from ($0.92) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avinger is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avinger is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvinger has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.32 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVGR Previous Symbol CUSIPN/A CIK1506928 Webwww.avinger.com Phone650-241-7900Debt Debt-to-Equity Ratio0.66 Current Ratio1.39 Quick Ratio1.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.13 million Price / Sales3.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book3.73Profitability EPS (Most Recent Fiscal Year)($3.18) Net Income$-19,450,000.00 Net Margins-225.26% Return on Equity-283.92% Return on Assets-75.72%Miscellaneous EmployeesN/A Outstanding Shares54,340,000Market Cap$28.39 million Next Earnings Date11/3/2020 (Estimated) OptionableNot Optionable $0.52 -0.01 (-1.75 %) (As of 08/12/2020 11:36 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AVGR News and Ratings via Email Sign-up to receive the latest news and ratings for AVGR and its competitors with MarketBeat's FREE daily newsletter. Avinger (NASDAQ:AVGR) Frequently Asked Questions How has Avinger's stock been impacted by COVID-19 (Coronavirus)? Avinger's stock was trading at $0.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AVGR stock has increased by 21.5% and is now trading at $0.5225. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Avinger? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avinger. When is Avinger's next earnings date? Avinger is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Avinger. How were Avinger's earnings last quarter? Avinger Inc (NASDAQ:AVGR) posted its quarterly earnings results on Thursday, July, 30th. The medical device company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.03. Avinger had a negative net margin of 225.26% and a negative return on equity of 283.92%. View Avinger's earnings history. When did Avinger's stock split? How did Avinger's stock split work? Avinger shares reverse split on Wednesday, January 31st 2018. The 1-40 reverse split was announced on Tuesday, January 30th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 30th 2018. An investor that had 100 shares of Avinger stock prior to the reverse split would have 3 shares after the split. What price target have analysts set for AVGR? 2 analysts have issued twelve-month target prices for Avinger's shares. Their forecasts range from $1.40 to $1.40. On average, they expect Avinger's share price to reach $1.40 in the next twelve months. This suggests a possible upside of 167.9% from the stock's current price. View analysts' price targets for Avinger. Has Avinger been receiving favorable news coverage? News coverage about AVGR stock has trended somewhat positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avinger earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Avinger. Are investors shorting Avinger? Avinger saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 208,700 shares, an increase of 115.6% from the February 27th total of 96,800 shares. Based on an average daily volume of 286,900 shares, the days-to-cover ratio is currently 0.7 days. View Avinger's Short Interest. Who are some of Avinger's key competitors? Some companies that are related to Avinger include Soliton (SOLY), Venus Concept (VERO), PAVmed (PAVM), BeyondAirInc . (XAIR), Spectral Medical (EDTXF), Neuronetics (STIM), Pro-Dex (PDEX), SANUWAVE Health (SNWV), Nephros (NEPH), BRAINSWAY LTD/S (BWAY), Titan Medical (TMDI), Nephros (NEPHD), AIT Therapeutics (AITB), DarioHealth (DRIO) and Delcath Systems (DCTH). View all competitors. What other stocks do shareholders of Avinger own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Novan (NOVN), Titan Pharmaceuticals (TTNP), BioNano Genomics (BNGO), Zosano Pharma (ZSAN), Matinas BioPharma (MTNB), AEterna Zentaris (AEZS), Actinium Pharmaceuticals (ATNM) and Biocept (BIOC). Who are Avinger's key executives? Avinger's management team includes the following people: Mr. Jeffrey M. Soinski, Pres, CEO & Director (Age 57)Mr. Mark B. Weinswig, Chief Financial Officer (Age 46)Mr. Himanshu N. Patel, Chief Technology Officer (Age 59)Mr. Keith Schaefer, Chief Operating OfficerMr. Philip R. Preuss, VP of Marketing & Bus. Operations (Age 41) When did Avinger IPO? (AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company acted as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers. What is Avinger's stock symbol? Avinger trades on the NASDAQ under the ticker symbol "AVGR." How do I buy shares of Avinger? Shares of AVGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Avinger's stock price today? One share of AVGR stock can currently be purchased for approximately $0.52. How big of a company is Avinger? Avinger has a market capitalization of $28.39 million and generates $9.13 million in revenue each year. The medical device company earns $-19,450,000.00 in net income (profit) each year or ($3.18) on an earnings per share basis. What is Avinger's official website? The official website for Avinger is www.avinger.com. How can I contact Avinger? Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The medical device company can be reached via phone at 650-241-7900 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
